- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03441139
Efficacy of Cryotherapy Combined or Not With Analgesics in Uncontrolled Painful Musculoskeletal Metastasis (CRYO)
Randomized Controlled Multicenter Prospective Open-label Study of the Efficacy of the Percutaneous Cryotherapy Combined or Not With a Medical Analgesia in the Treatment of Patients With Uncontrolled Painful Musculoskeletal Metastasis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There is a substantial body of evidences that support the rationale for percutaneous cryotherapy in the treatment of painful musculoskeletal metastasis. Since the available results are based exclusively on retrospective and single-arm prospective studies, all authors agree that preliminary data deserves further investigation to provide high level evidences.
Current knowledge, along with the need for relieving patients' pain, already leads interventional radiologists to introduce analgesic cryotherapy in their routine practice. Our team usually notes a clinically significant pain relief that is immediate, continuous and prolonged in these patients. However, facing the lack of comparative studies, this technique is still proposed to patients with poor life-expectancy.
Percutaneous cryotherapy is an innovative strategy in the treatment of patients with uncontrolled painful metastases. It could provide a significant and durable pain relief and a better quality of life, earlier in the patient's care pathway.
The study group hypotheses that an early procedure of percutaneous cryotherapy is able to provide painful patients with better and prolonged analgesia and quality of life.
A prospective controlled study is proposed with two analgesic strategies (percutaneous cryotherapy plus medical supportive care versus medical supportive care alone) in patients with a painful metastasis not controlled by conventional analgesia strategy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- Institut Bergonie
-
Lyon, France, 69008
- Centre Léon Bérard
-
Marseille, France, 13273
- Institut Paoli Calmettes
-
Montpellier, France, 34298
- Institut de Cancérologie de Montpellier-Val d'Aurelle
-
Saint-Herblain, France, 44805
- Institut de Cancérologie de l'Ouest - Centre René Gauducheau
-
Strasbourg, France, 67065
- Institut Paul Strauss
-
Strasbourg, France, 67091
- CHRU de Strasbourg
-
Villejuif, France, 94805
- Institut Gustave Roussy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years at the day of consenting to the study;
- Patient with at least 1 painful metastasis with a musculoskeletal involvement;
- Patient referred to a Pain Management Unit to optimize the analgesic strategy;
Painful metastatic lesion that fulfils with all the following :
- Pain must be correlated with an identifiable lesion on imaging (Computed Tomography, Magnetic Resonance Imaging or Ultrasonography)
- Level of mean pain within the past 24 hours of at least 4/10 (numeric rating scale)
- Painful metastasis suitable for a procedure of percutaneous cryotherapy
- Life-expectancy longer than 6 months;
- Performance Status of the ECOG ≤2;
- Neutrophils count > 1 Gi/l within the past 14 days;
- Adequate coagulation panel (as per the investigator judgement);
- Ability to understand and willingness for follow-up visits;
- Covered by a medical insurance;
- Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrolment.
Exclusion Criteria:
- Patient with a primary tumor of leukemia, lymphoma or myeloma;
- Tumor involving a weight bearing long bone of the lower limbs with the tumor causing more than 50% of cortical bone;
- Lesion amenable to any curative intervention;
- Formal indication for local analgesic procedure other than percutaneous cryotherapy;
- Prior radiotherapy on the targeted lesion within the 3 weeks prior to randomization;
- Patient with any contraindication for the procedure of percutaneous cryotherapy, including treatment requiring ice ball formation within 0.5 cm of the spinal cord, brain, other critical nerve, structure, large abdominal vessels such as the aorta or inferior vena cava, bowel or bladder (except if active or passive thermic protection can be performed);
- Uncontrolled coagulopathy or bleeding disorders;
- Evidence of pregnancy, breast-feeding, or patient wishing to become pregnant during the study;
- Active, uncontrolled infection;
- Any cognitive impairment or any disease that may restrain the use of numeric scales and the administration of quality of life questionnaires;
- Clinically significant unrelated systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would likely interfere with study procedures or results;
- Concurrent participation in other experimental studies that could interfere with the primary endpoint assessment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cryotherapy + medical analgesics
Percutaneous Cryotherapy and medical analgesics according to the investigator's discretion
|
Percutaneous cryotherapy: A complete cycle of treatment will require 2 freezing 10-minutes periods, separate by a 9-minutes passive and 1-minute active thaw, with the cryoablation system. Dimension of the iceball coverage above the tumor will be monitored by non-contrast CT or MRI during the freezing cycle. Medical supportive care: Best analgesic therapy at investigator's discretion
Other Names:
|
Active Comparator: Medical analgesics
Medical analgesics alone according to the investigator's discretion
|
Best analgesic therapy at investigator's discretion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to analgesic strategy failure
Time Frame: Time from the date of randomization to the date of analgesic strategy failure assessed up to 6 months
|
Failure will be defined as at least, one of the following situations: Reescalation of the mean local pain by 2 points or more from the lowest pain score from baseline; Absence of pain relief ≥ 2 points 3 months after randomization; Indication of any other loco regional analgesic procedure (radiotherapy, interventional radiology or surgery).
|
Time from the date of randomization to the date of analgesic strategy failure assessed up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of pain relief
Time Frame: Weekly for the first 3 months, then monthly assessed up to 6 months
|
Percentage of pain relief from baseline, rated by patients
|
Weekly for the first 3 months, then monthly assessed up to 6 months
|
Depth of local pain relief
Time Frame: Numeric rating scale (scale range from 0 [no pain] to 10 [worst imaginable pain]): Weekly for the first 3 months, then monthly assessed up to 6 months
|
Evaluation using the numeric rating scale
|
Numeric rating scale (scale range from 0 [no pain] to 10 [worst imaginable pain]): Weekly for the first 3 months, then monthly assessed up to 6 months
|
Depth of local pain relief
Time Frame: Brief Pail Inventory : Monthly assessment up to 6 months
|
Evaluation using the Brief Pain Inventory
|
Brief Pail Inventory : Monthly assessment up to 6 months
|
The impact of local pain on the patient's quality of life
Time Frame: Monthly assessment up to 6 months
|
Using the FACT-BP questionnaire
|
Monthly assessment up to 6 months
|
The impact of local pain on the patient's quality of life
Time Frame: Monthly assessment up to 6 months
|
Using the EuroQOL-5Dimensions-5Levels questionnaire
|
Monthly assessment up to 6 months
|
Description of analgesic consumption
Time Frame: Weekly for the first 3 months, then monthly assessed up to 6 months
|
Using a booklet completed by the patients and/or the investigator
|
Weekly for the first 3 months, then monthly assessed up to 6 months
|
Overall Survival
Time Frame: From date of randomization to date of death from any cause or date of LPLV (estimated date: March 2020)
|
Time from the date of randomization to the date of death due to any cause
|
From date of randomization to date of death from any cause or date of LPLV (estimated date: March 2020)
|
Tolerance profile
Time Frame: Date of last visit (Month 6 +/- 28 days)
|
Tolerance assessed according to the NCI-CTC AE version 4
|
Date of last visit (Month 6 +/- 28 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cost-effectiveness analysis
Time Frame: Date of last visit (Month 6 +/- 28 days)
|
All the resources consumption will be collected during the 6-months timeframe: Hospitalization costs (outpatient, inpatient, and home care), external consultations and wider examinations (eg MRI), transportation costs.
|
Date of last visit (Month 6 +/- 28 days)
|
Cost-utility analysis
Time Frame: Date of last visit (Month 6 +/- 28 days)
|
All the resources consumption will be collected during the 6-months timeframe: Hospitalization costs (outpatient, inpatient, and home care), external consultations and wider examinations (eg MRI), transportation costs.
|
Date of last visit (Month 6 +/- 28 days)
|
Budget impact analyses
Time Frame: One-year baseline period. Will be performed in case the experimental strategy dominates the standard strategy
|
Quantication of financial consequences of rolling out the innovative strategy throughout the health system (i.e. the replacement of Medical supportive care by Medical supportive care + Percutaneous cryotherapy)
|
One-year baseline period. Will be performed in case the experimental strategy dominates the standard strategy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Charles MASTIER, MD, Centre Léon Bérard
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ET17-016 (Cryoanalgesia)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Musculoskeletal Pain
-
Sykehuset i Vestfold HFActive, not recruitingBack Pain | Musculoskeletal Pain | Chronic Pain | Musculoskeletal Diseases or Conditions | Pain, Chronic | Musculoskeletal Disorder | Musculoskeletal Neck PainNorway
-
University of Missouri, Kansas CityTerminatedOrthopaedic Related Pain (Musculoskeletal Pain)United States
-
Uppsala UniversityDalarna County Council, Sweden; Center for Clinical Research Dalarna, Sweden; REHSAM, SwedenTerminatedMusculoskeletal Neck Pain | Musculoskeletal Shoulder PainSweden
-
NORCE Norwegian Research Centre ASHelse Sor-Ost; Sykehuset i Vestfold HFCompletedNeck Pain Musculoskeletal | Back Pain Lower BackNorway
-
Massachusetts General HospitalOrthopaedic Trauma AssociationCompleted
-
Wayne State UniversityUniversity of Southern CaliforniaCompleted
-
Wayne State UniversityUniversity of MichiganCompleted
-
Wayne State UniversityBlue Cross Blue Shield of Michigan FoundationCompleted
-
Stanford UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingPain | Joint Pain | Pain, Chronic | Chronic Musculoskeletal PainUnited States
Clinical Trials on Cryotherapy + Medical analgesics
-
Preventive Oncology International, Inc.Peking University Shenzhen HospitalCompletedCervical Cancer | Cervical Intraepithelial Neoplasia | Human Papillomavirus | Cervical Dysplasia | Cervical NeoplasmChina
-
Brigham and Women's HospitalRecruitingNeuralgia | Neuropathy | Facet Joints; DegenerationUnited States
-
Massachusetts General HospitalCompletedBarrett's EsophagusUnited States
-
University Hospital, MontpellierCryoMed MillenaireRecruitingBreast Cancer | Aromatase InhibitorsFrance
-
EDAP TMS S.A.UnknownProstate CancerUnited States, Canada
-
Walter Reed National Military Medical CenterRecruitingCryotherapy Effect | Postoperative Pain Management | CompressionUnited States
-
Cairo UniversityNot yet recruiting
-
Creighton UniversityCompleted
-
Azienda Ospedaliera San Camillo ForlaniniCompleted
-
Hanyang University Seoul HospitalCompletedCryotherapy EffectKorea, Republic of